EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Non‐Invasive Estimation of Systemic Drug Exposure Using Exhaled Breath Metabolomics in Humans: A Translational Proof‐of‐Concept Study

Kai Fricke iD, Diego M Baur iD, Kapil Dev Singh iD, Felix Schmidt, Kathrin Müsch, Noriane A Sievi iD, Marco Di Donato iD, Anton Schmick iD, Jonas Herth iD, Silvia Ulrich iD, Pablo Sinues iD, Marian Galovic iD und 1 weitere

Clinical Pharmacology & Therapeutics · 07.08.2026

DOI: 10.1002/cpt.70437 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 07.08.2026. Verfasst von Kai Fricke und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonology, University Hospital Zurich, Zurich, Switzerland. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Lotte and Adolf Hotz-Sprenger Foundation, Schwyzer Foundation, Uniscientia Foundation.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Accurate assessment of systemic drug exposure in humans remains challenging, as conventional approaches rely on intermittent blood sampling and laboratory‐based assays that are invasive and provide limited temporal resolution. Exhaled breath contains volatile and semi‐volatile compounds arising from drug metabolism and downstream biological processes, suggesting that it may serve as a non‐invasive matrix for integrated pharmacokinetic sensing. We conducted a prospective observational study using exhaled breath metabolomics based on secondary electrospray ionization high‐resolution mass spectrometry (SESI‐HRMS) to estimate systemic drug exposure from a breath‐sampling session. A total of 117 adults provided 127 paired breath–serum measurements under routine outpatient conditions. Model performance was evaluated using repeated k‐fold cross‐validation and quantified using concordance correlation coefficients. Breath‐derived estimates of valproic acid, levetiracetam, lamotrigine, and lacosamide showed moderate concordance with measured serum concentrations, with concordance correlation coefficients ranging from 0.733 to 0.895 across medications. The lacosamide findings should be considered preliminary because of the limited subgroup size ( n = 16). The observed concordance supports proof‐of‐concept exposure estimation but does not establish clinical interchangeability with serum‐based therapeutic drug monitoring. The previously defined 11‐feature VPA breath signature retained predictive utility in a separate adult cohort, supporting its cross‐cohort transferability within the present analytical framework. These findings support the feasibility of exhaled breath analysis for non‐invasive estimation of systemic drug exposure across pharmacologically distinct medications. Breath analysis should currently be considered complementary to serum‐based monitoring, and external multicenter and longitudinal validation is required before clinical implementation.

Autor:innen und Institutionen

  • Department of Pulmonology, University Hospital Zurich, Zurich, Switzerland.
  • Faculty of Medicine, University of Zurich, Zurich, Switzerland.
  • University Children's Hospital Basel, Basel, Switzerland.
  • Department of Biomedical Engineering, University of Basel, Basel, Switzerland.
  • Department of Neurology, University Hospital Zurich, Zurich, Switzerland.

ORCID-Profile: Kai Fricke, Diego M Baur, Kapil Dev Singh, Noriane A Sievi, Marco Di Donato, Anton Schmick, Jonas Herth, Silvia Ulrich, Pablo Sinues, Marian Galovic, Malcolm Kohler

Förderung

  • Lotte and Adolf Hotz-Sprenger Foundation
  • Schwyzer Foundation
  • Uniscientia Foundation
  • Lunge Zürich
  • Foundation Botnar (Switzerland)
  • Swiss National Science Foundation
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung

Zitieren

APA

Fricke, K., Baur, D. M., Singh, K. D., Schmidt, F., Müsch, K., Sievi, N. A., Di Donato, M., Schmick, A., Herth, J., Ulrich, S., Sinues, P., Galovic, M., & Kohler, M. (2026). Non‐Invasive Estimation of Systemic Drug Exposure Using Exhaled Breath Metabolomics in Humans: A Translational Proof‐of‐Concept Study. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70437

Vancouver

Fricke K, Baur DM, Singh KD, Schmidt F, Müsch K, Sievi NA, et al. Non‐Invasive Estimation of Systemic Drug Exposure Using Exhaled Breath Metabolomics in Humans: A Translational Proof‐of‐Concept Study. Clinical Pharmacology & Therapeutics. 2026. doi:10.1002/cpt.70437

BibTeX
@article{Fricke2026,
  author = {Fricke, Kai and Baur, Diego M and Singh, Kapil Dev and Schmidt, Felix and Müsch, Kathrin and Sievi, Noriane A and Di Donato, Marco and Schmick, Anton and Herth, Jonas and Ulrich, Silvia and Sinues, Pablo and Galovic, Marian and Kohler, Malcolm},
  title = {Non‐Invasive Estimation of Systemic Drug Exposure Using Exhaled Breath Metabolomics in Humans: A Translational Proof‐of‐Concept Study},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2026},
  doi = {10.1002/cpt.70437}
}
Kostenlos starten →